Proscia Concentriq LS
Proscia Concentriq LS
At Proscia, we’re rewiring pathology for precision medicine – enabling pharmaceutical and biotech companies to accelerate drug development, and empowering CROs to deliver higher-quality, faster studies for their sponsor partners. We do this through Concentriq® LS, our enterprise platform trusted by 16 of the top 20 global pharmaceutical companies.
Serving as the central hub for image-based scientific workflows from biomarker discovery to clinical trial execution, Concentriq LS unifies data, teams, and AI to unlock insights and accelerate R&D pipelines.
Reach Milestones Faster, With Greater Confidence
Life sciences organizations need pathology infrastructure built for the speed and complexity of AI-driven drug development. The platform accelerates scientific workflows with seamless AI image analysis and robust collaboration tools while maintaining GxP compliance. It also centralizes enterprise pathology data, transforming siloed assets into a digital foundation optimized for AI development and discovery.
Platform-wide capabilities:
- Universal Scanner & Format Compatibility: scanner support (Aperio, Hamamatsu, 3DHISTECH, Zeiss, Leica, Philips) and major WSI formats (DICOM, OME-TIFF, SVS, NDPI, MRXS)
- Open API: Integrate image analysis applications—whether developed by other third parties or in-house development teams—directly into routine workflows using Concentriq’s open API
- Concentriq Embeddings: Data science and AI teams can quickly, efficiently, and securely feed pathology data into leading foundation models to generate embeddings, dramatically expediting the model development process
- Standardized Study Templates: Configure standardized study templates to define critical assessment parameters, enhance efficiency, and improve quality of research data
- Built-in Compliance: Advanced compliance features (from filterable, exhaustive, easy-to-read audit logs to reason for change and beyond), experienced system validation support, and ISO 27001 certification work together to empower your organization to meet GLP and GCP compliance and ensure data is submission-ready to regulators
Discovery: Accelerate Biomarker Discovery & Target Validation
Enable discovery teams to explore pathology data, validate biomarkers, and develop AI models at scale. Centralizes digital slides, metadata, annotations, and analysis tools to support translational research and early discovery workflows.
- Global search to surface historical slides and datasets for retrospective analysis and AI training
- Advanced annotation tools, including Magnetic Brush, for precise, reproducible tissue markup
- Build and validate AI models using internal datasets and Proscia-enabled real-world pathology cohorts
- Leverage the AI-Partner ecosystem, including Visiopharm, Ibex, MindPeak, and Nucleiai
Preclinical Development: Standardize Toxicology Studies
Support GLP-aligned studies with validated workflows, compliance controls, and collaborative review tools that ensure data integrity and regulatory readiness.
- GxP tool-kit and validation services to support GLP-ready deployment
- Audit trails, electronic signatures, and role-based access control
- Automated AI quality control to detect artifacts prior to analysis and support consistent image quality
- Standardized workflows across internal teams, global sites, and CRO partners
Clinical Development: Streamline Trials & Maximize Success
Support clinical trials with pathology infrastructure designed for efficiency, reproducibility, and global collaboration across sponsors, CROs, and central laboratories.
- Maintain continuity of pathology images, metadata, and annotations as studies transition from preclinical to clinical phases
- Speed up pathologist recruitment and onboarding with an intuitive, globally accessible platform, enabling faster project starts working with colleagues far and wide
- Support reproducible analysis through standardized results and AI-based biomarkers for patient stratification
Unlocking Drug Development’s Greatest Asset
Proscia Aperture is a precision medicine solution that surfaces patient insights at the moment of diagnosis, powered by a global network of diagnostic labs reviewing 8M+ cases annually on the Concentriq platform. Seamlessly connected to Concentriq LS, Aperture enables biopharma companies to accelerate drug development and generate real-world evidence across the precision medicine lifecycle – from discovery through clinical development and commercialization.
- Surface patients at the point of diagnosis using real-time AI-powered analysis of daily cases from a global diagnostic network
- Model disease and biomarker prevalence to refine eligibility criteria and inform trial design
- Monitor enrollment with real-time dashboards and notifications as qualified candidates are surfaced
- Deploy and optimize companion diagnostic algorithms using real-world data from the diagnostic network
- Generate regulatory-grade real-world evidence for submissions, label expansions, and market access
Enterprise-Grade Security, Compliance & Regulatory Readiness
Concentriq is built to operate in highly regulated environments, providing encryption, audit logging, access controls, and SSO to support secure, compliant digital pathology workflows. All deployments meet HIPAA and GDPR requirements.
- 8M+ patients diagnosed in Concentriq in 2025 (32k+ daily)
- High trust software – ISO 27001 certified, SOC 2 Type II attested, and more — Concentriq meets the highest global standards
- GLP workflows validated for preclinical safety studies with validation starter kits and services

Drive R&D Success with Expert, Comprehensive Guidance & Support
Proscia’s customer success, Professional Services, and Technical Support teams support deployment, workflow integration, and operational scaling of Concentriq environments.
- Expert implementation that accelerates time to value with tailored solution architecture
- Enterprise-grade, reliable SLA-driven support tailored to your organization
- Dedicated Customer Success Manager provides guidance and strategy to achieve business objectives
- Ongoing adoption support for new features and integrations
Discover how Concentriq LS can accelerate your R&D from discovery through clinical development. Contact our Life Sciences team to schedule a personalized demo.
More Solutions from Proscia
Compare Solutions
Get Pathology News Delivered to Your Inbox
Learn More
Proscia News
Proscia Receives New FDA 510(k) Clearance for Concentriq AP-Dx with Predetermined Change Control Plan
Editor2026-08-06T18:10:26+00:00August 6, 2026|
How We Built Intelligence into the Pathology Platform
Editor2026-07-24T14:44:58+00:00July 20, 2026|
Proscia Launches Fifth Generation of Concentriq, Bringing the Latest Advancements in AI to Pathologists and Scientists
Editor2026-06-23T15:32:27+00:00June 17, 2026|
NextGen Pathology Selects Proscia to Establish AI Foundation for Business Growth
Editor2026-06-11T16:01:23+00:00June 3, 2026|
Reflections on KLAS’ US Digital Pathology Report: What it Means to Be a Long-Term Partner
Editor2026-05-15T14:41:12+00:00May 12, 2026|
Proscia Wins 2026 MedTech Breakthrough Award for Turning the Moment of Diagnosis into Drug Development Insights
Editor2026-05-13T11:19:48+00:00May 8, 2026|
From Glass Slide to Molecular Proxy: The Pathology AI Convergence at AACR 2026
Editor2026-05-12T12:58:29+00:00May 7, 2026|

















